BACKGROUND: Cell selection is an important part of manufacturing cellular therapies. A new highly automated instrument, the CliniMACS Prodigy (Miltenyi Biotec), was evaluated for the selection of CD34+ cells from mobilized peripheral blood stem cell (PBSC) concentrates using monoclonal antibodies conjugated to paramagnetic particles. STUDY DESIGN AND METHODS: PBSCs were collected by apheresis from 36 healthy subjects given granulocyte-colony-stimulating factor (G-CSF) or G-CSF plus plerixafor. CD34+ cells from 11 PBSC concentrates were isolated with the automated CliniMACS Prodigy and 25 with the semiautomated CliniMACS Plus Instrument. RESULTS: The proportion of CD34+ cells in the selected products obtained with the two instruments was similar: 93.6 ± 2.6% for the automated and 95.7 ± 3.3% for the semiautomated instrument (p > 0.05). The recovery of CD34+ cells from PBSC concentrates was less for the automated than the semiautomated instrument (51.4 ± 8.2% vs. 65.1 ± 15.7%; p = 0.019). The selected products from both instruments contained few and similar quantities of platelets (PLTs) and red blood cells. The depletion of CD3+ cells was less with the automated instrument (4.34 ± 0.2 log depletion vs. 5.20 ± 0.35 log depletion; p < 1 × 10(-6) ). Removal of PLTs from PBSC concentrates by washing was associated with better CD34+ cell recovery. We explored the reasons for lower CD34+ cell recovery by the Prodigy and found that the nonselected cells for the Prodigy contained more PLTs than those for the CliniMACS Plus. CONCLUSIONS: CD34+ cells can be effectively selected from mobilized PBSC concentrates with the CliniMAC Prodigy, but the recovery of CD34+ cells and depletion of CD3+ cells was lower than with the semiautomated CliniMACS Plus Instrument.
BACKGROUND: Cell selection is an important part of manufacturing cellular therapies. A new highly automated instrument, the CliniMACS Prodigy (Miltenyi Biotec), was evaluated for the selection of CD34+ cells from mobilized peripheral blood stem cell (PBSC) concentrates using monoclonal antibodies conjugated to paramagnetic particles. STUDY DESIGN AND METHODS: PBSCs were collected by apheresis from 36 healthy subjects given granulocyte-colony-stimulating factor (G-CSF) or G-CSF plus plerixafor. CD34+ cells from 11 PBSC concentrates were isolated with the automated CliniMACS Prodigy and 25 with the semiautomated CliniMACS Plus Instrument. RESULTS: The proportion of CD34+ cells in the selected products obtained with the two instruments was similar: 93.6 ± 2.6% for the automated and 95.7 ± 3.3% for the semiautomated instrument (p > 0.05). The recovery of CD34+ cells from PBSC concentrates was less for the automated than the semiautomated instrument (51.4 ± 8.2% vs. 65.1 ± 15.7%; p = 0.019). The selected products from both instruments contained few and similar quantities of platelets (PLTs) and red blood cells. The depletion of CD3+ cells was less with the automated instrument (4.34 ± 0.2 log depletion vs. 5.20 ± 0.35 log depletion; p < 1 × 10(-6) ). Removal of PLTs from PBSC concentrates by washing was associated with better CD34+ cell recovery. We explored the reasons for lower CD34+ cell recovery by the Prodigy and found that the nonselected cells for the Prodigy contained more PLTs than those for the CliniMACS Plus. CONCLUSIONS:CD34+ cells can be effectively selected from mobilized PBSC concentrates with the CliniMAC Prodigy, but the recovery of CD34+ cells and depletion of CD3+ cells was lower than with the semiautomated CliniMACS Plus Instrument.
Authors: Veronika Bachanova; Linda J Burns; David H McKenna; Julie Curtsinger; Angela Panoskaltsis-Mortari; Bruce R Lindgren; Sarah Cooley; Daniel Weisdorf; Jeffrey S Miller Journal: Cancer Immunol Immunother Date: 2010-08-03 Impact factor: 6.968
Authors: R Nakamura; E Bahceci; E J Read; S F Leitman; C S Carter; R Childs; C E Dunbar; R Gress; R Altemus; N S Young; A J Barrett Journal: Br J Haematol Date: 2001-10 Impact factor: 6.998
Authors: Veronika Bachanova; Sarah Cooley; Todd E Defor; Michael R Verneris; Bin Zhang; David H McKenna; Julie Curtsinger; Angela Panoskaltsis-Mortari; Dixie Lewis; Keli Hippen; Philip McGlave; Daniel J Weisdorf; Bruce R Blazar; Jeffrey S Miller Journal: Blood Date: 2014-04-09 Impact factor: 22.113
Authors: Carolyn A Keever-Taylor; Steven M Devine; Robert J Soiffer; Adam Mendizabal; Shelly Carter; Marcelo C Pasquini; Parameswaran N Hari; Anthony Stein; Hillard M Lazarus; Charles Linker; Steven C Goldstein; Edward A Stadtmauer; Richard J O'Reilly Journal: Biol Blood Marrow Transplant Date: 2011-08-26 Impact factor: 5.742
Authors: Melissa A Geller; Sarah Cooley; Patricia L Judson; Rahel Ghebre; Linda F Carson; Peter A Argenta; Amy L Jonson; Angela Panoskaltsis-Mortari; Julie Curtsinger; David McKenna; Kathryn Dusenbery; Robin Bliss; Levi S Downs; Jeffrey S Miller Journal: Cytotherapy Date: 2010-09-20 Impact factor: 5.414
Authors: Aldemar Montero; Bipin N Savani; Aarthi Shenoy; Elizabeth J Read; Charles S Carter; Susan F Leitman; Stephan Mielke; Katayoun Rezvani; Richard Childs; A John Barrett Journal: Biol Blood Marrow Transplant Date: 2006-12 Impact factor: 5.742
Authors: Daniel H Fowler; Miriam E Mossoba; Seth M Steinberg; David C Halverson; David Stroncek; Hahn M Khuu; Frances T Hakim; Luciano Castiello; Marianna Sabatino; Susan F Leitman; Jacopo Mariotti; Juan C Gea-Banacloche; Claude Sportes; Nancy M Hardy; Dennis D Hickstein; Steven Z Pavletic; Scott Rowley; Andre Goy; Michele Donato; Robert Korngold; Andrew Pecora; Bruce L Levine; Carl H June; Ronald E Gress; Michael R Bishop Journal: Blood Date: 2013-02-20 Impact factor: 22.113
Authors: B S Cho; K S Eom; Y J Kim; H J Kim; S Lee; C K Min; S G Cho; W S Min; C W Park; C C Kim; J W Lee Journal: Bone Marrow Transplant Date: 2010-01-11 Impact factor: 5.483
Authors: Sandhya R Panch; Thejaswi Bikkani; Vanessa Vargas; Jolynn Procter; James W Atkins; Virginia Guptill; Karen M Frank; Anna F Lau; David F Stroncek Journal: Biol Blood Marrow Transplant Date: 2018-08-09 Impact factor: 5.742